THE EFFECT OF INFLIXIMAB TREATMENT ON INSULIN RESISTANCE IN PATIENTS WITH RHEUMATOID ARTHRITIS

REFERENCES

• Kaplan M J. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol. 2006; 18: 289–97.
   Web of Science ®Google Scholar
• Gonzalez-Gay MA, Gonzalez-Juanatey C, Martini. Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol. 2006; 24: 115–7.
   PubMed Web of Science ®Google Scholar
• Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol. 2003; 30: 1403–5.
   PubMed Web of Science ®Google Scholar
• Borst SE.The role of INF-a in insulin resistance. Endocrine. 2004; 23:177–82.
   PubMed Web of Science ®Google Scholar
• Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005; 5: 70–5.
   PubMedGoogle Scholar
• Moller DE. Potential role of INF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000; 11:212–7.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259:87–91.
   PubMed Web of Science ®Google Scholar
• Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome.Arch Intern Med. 2006; 166:902–8.
   Google Scholar
• St Clair EW. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis. 2002;61 Suppl 2: ii67–9.
   Google Scholar
• Yazdani-Biuki B, SteLzi H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-INF-alpha antibody infliximab. Eurl Clin Invest. 2004; 34: 641–2.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005; 64: 765–6.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumour necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheu-matol. 2006; 24: 83–6.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheu-matism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315–24.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38:44–8.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheu-matoid arthritis. Arthritis Rheum. 1995; 38: 727–35.
   PubMed Web of Science ®Google Scholar
• Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care. 1997; 20: 1744–66.
   PubMed Web of Science ®Google Scholar
• Levy IC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA). Evaluation uses the computer program. Diabetes Care. 1998; 21: 2191–2.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Gonzalez-Juanatey C, Martini. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005; 35: 8–17.
   PubMed Web of Science ®Google Scholar
• Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumour necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes.J Vasc Res. 2005; 42: 517–25.
   PubMed Web of Science ®Google Scholar
• Gentile S, Guarino G, Bizzarro A, De BellisA, Torella R. Infliximab does not interfere with insulin secretion, insulin resistance and production of GAD and islet cell antibodies in patients with Crohn's disease. Diabet Obes Metab. 2002; 4: 276–7.
   Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004; 351: 1106-18.
   Google Scholar
• Giordano M, Matsuda M, Sanders L, Canessa ML, DeFronzo RA. Effects of a ngiotensin-converting enzyme inhibitors, Ca2+ chan-nel antagonists, and alpha-adrenergic Mockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabe-tes. 1995; 44: 665–71.
   PubMed Web of Science ®Google Scholar
• Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991; 14: 203–9.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365:1415–28.
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of the National Choles-terol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. (Adult Treatment Panel III). JAMA. 2001; 285: 2486–97.
   Web of Science ®Google Scholar